Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omalizumab in uncontrolled allergic asthma despite GINA step 4 therapy
CTR20131579Phase 3Completed
- Sponsor
- Novartis
- Start
- May 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of omalizumab in allergic asthma, sponsored by Novartis. Started May 2014; status: completed.
02
Drugs
omalizumab
03
Conditions
allergic asthma
Beyond the preview
Go deeper on CTR20131579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20131579.